Evidence map›Paper›PMID 38435714›Full record

ArticleJournal of dermatology and skin science2023

The Dawning of a New Enterprise: RNA Therapeutics for the Skin.

Rachel E Kieser, Shaheerah Khan, Nada Bejar, Daniel L Kiss

Abstract read
In one paragraph

Article in Journal of dermatology and skin science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Gene Therapies in Dermatological Diseases: A Breakthrough in Treatment.International journal of molecular sciences · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rachel E KieserCenter for RNA Therapeutics.ORCID 0000-0003-1820-0193
Shaheerah KhanCenter for RNA Therapeutics.ORCID 0000-0003-3146-0440
Nada BejarCenter for RNA Therapeutics.ORCID 0000-0002-0980-5951
Daniel L KissCenter for RNA Therapeutics.ORCID 0000-0001-5033-7160

Funding

Discovery of novel synthetic IL-1 adjuvants75N93019C00045 · NIAID · UNIVERSITY OF MONTANA · PI EVANS, JAY · 2019 to 2024
$18.5M
Understanding the mechanisms that regulate cytoplasmic capping and defining itscontributions to post-transcriptional gene regulation (Same as parent grant)R35GM137819 · NIGMS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI KISS, DANIEL LOUIS · 2020 to 2024
$2.3M
NIAID NIH HHS 75N93019C00045NIGMS NIH HHS R35 GM137819
6 · The paper itself

Abstract

Despite being under development for decades, RNA therapeutics have only recently emerged as viable drug platforms. The COVID-19 mRNA vaccines have demonstrated the promise and power of the platform technology. In response, novel RNA drugs are entering clinical trials at an accelerating rate. As the skin is the largest and most accessible organ, it has always been a preferred target for drug discovery. This holds true for RNA therapies as well, and multiple candidate RNA-based drugs are currently in development for an array of skin conditions. In this mini review, we catalog the RNA therapies currently in clinical trials for different dermatological diseases. We summarize the main types of RNA-related drugs and use examples of drugs currently in development to illustrate their key mechanism of action.

Indexed as

Antisense oligonucleotide therapeuticsASODermatologyHypertrophic scarsMelanomamRNA therapeuticsRNA therapeuticssiRNA therapeuticsSkinWound healing

Identifiers

PMID38435714
PMCPMC10907068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.